HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells

Autophagy drives compartment-specific oncogenesis

Barbara Chiavarina, Diana Whitaker-Menezes, Gemma Migneco, Ubaldo E. Martinez-Outschoorn, Stephanos Pavlides, Anthony Howell, Herbert B. Tanowitz, Mathew C. Casimiro, Chenguang Wang, Richard G. Pestell, Philip Grieshaber, Jaime Caro, Federica Sotgia, Michael P. Lisanti

Research output: Contribution to journalArticle

143 Citations (Scopus)

Abstract

Our recent studies have mechanistically implicated a loss of stromal Cav-1 expression and HIF1-alpha-activation in driving the cancer-associated fibroblast phenotype, through the paracrine production of nutrients via autophagy and aerobic glycolysis. However, it remains unknown if HIF1a-activation is sufficient to confer the cancer-associated fibroblast phenotype. To test this hypothesis directly, we stably-expressed activated HIF1a in fibroblasts and then examined their ability to promote tumor growth using a xenograft model employing human breast cancer cells (MDA-MB-231). Fibroblasts harboring activated HIF1a showed a dramatic reduction in Cav-1 levels and a shift towards aerobic glycolysis, as evidenced by a loss of mitochondrial activity, and an increase in lactate production. Activated HIF1a also induced BNIP3 and BNIP3L expression, markers for the autophagic destruction of mitochondria. Most importantly, fibroblasts expressing activated HIF1a increased tumor mass by ∼2-fold and tumor volume by ∼3-fold, without a significant increase in tumor angiogenesis. In this context, HIF1a also induced an increase in the lymph node metastasis of cancer cells. Similar results were obtained by driving NFκB activation in fibroblasts, another inducer of autophagy. Thus, activated HIF1a is sufficient to functionally confer the cancer-associated fibroblast phenotype. It is also known that HIF1a expression is required for the induction of autophagy in cancer cells. As such, we next directly expressed activated HIF1a in MDA-MB-231 cells and assessed its effect on tumor growth via xenograft analysis. Surprisingly, activated HIF1a in cancer cells dramatically suppressed tumor growth, resulting in a 2-fold reduction in tumor mass and a 3-fold reduction in tumor volume. We conclude that HIF1a activation in different cell types can either promote or repress tumorigenesis. Based on these studies, we suggest that autophagy in cancer-associated fibroblasts promotes tumor growth via the paracrine production of recycled nutrients, which can directly "feed" cancer cells. Conversely, autophagy in cancer cells represses tumor growth via their "self-digestion". Thus, we should consider that the activities of various known oncogenes and tumor-suppressors may be compartment and cell-type specific, and are not necessarily an intrinsic property of the molecule itself. As such, other "classic" oncogenes and tumor suppressors will have to be re-evaluated to determine their compartment specific effects on tumor growth and metastasis. Lastly, our results provide direct experimental support for the recently proposed "Autophagic Tumor Stroma Model of Cancer".

Original languageEnglish (US)
Pages (from-to)3534-3551
Number of pages18
JournalCell Cycle
Volume9
Issue number17
DOIs
StatePublished - Sep 1 2010

Fingerprint

Autophagy
Carcinogens
Carcinogenesis
Breast Neoplasms
Neoplasms
Growth
Fibroblasts
Cancer-Associated Fibroblasts
Glycolysis
Tumor Burden
Phenotype
Oncogenes
Heterografts
Neoplasm Metastasis
Food

Keywords

  • Autophagy
  • Cancer associated fibroblasts
  • Caveolin-1
  • Compartment-specific oncogenesis
  • HIF1A
  • Hypoxia
  • Mitophagy
  • NFκB
  • The Warburg effect
  • Tumor stroma

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology
  • Developmental Biology

Cite this

Chiavarina, B., Whitaker-Menezes, D., Migneco, G., Martinez-Outschoorn, U. E., Pavlides, S., Howell, A., ... Lisanti, M. P. (2010). HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: Autophagy drives compartment-specific oncogenesis. Cell Cycle, 9(17), 3534-3551. https://doi.org/10.4161/cc.9.17.12908

HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells : Autophagy drives compartment-specific oncogenesis. / Chiavarina, Barbara; Whitaker-Menezes, Diana; Migneco, Gemma; Martinez-Outschoorn, Ubaldo E.; Pavlides, Stephanos; Howell, Anthony; Tanowitz, Herbert B.; Casimiro, Mathew C.; Wang, Chenguang; Pestell, Richard G.; Grieshaber, Philip; Caro, Jaime; Sotgia, Federica; Lisanti, Michael P.

In: Cell Cycle, Vol. 9, No. 17, 01.09.2010, p. 3534-3551.

Research output: Contribution to journalArticle

Chiavarina, B, Whitaker-Menezes, D, Migneco, G, Martinez-Outschoorn, UE, Pavlides, S, Howell, A, Tanowitz, HB, Casimiro, MC, Wang, C, Pestell, RG, Grieshaber, P, Caro, J, Sotgia, F & Lisanti, MP 2010, 'HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: Autophagy drives compartment-specific oncogenesis', Cell Cycle, vol. 9, no. 17, pp. 3534-3551. https://doi.org/10.4161/cc.9.17.12908
Chiavarina, Barbara ; Whitaker-Menezes, Diana ; Migneco, Gemma ; Martinez-Outschoorn, Ubaldo E. ; Pavlides, Stephanos ; Howell, Anthony ; Tanowitz, Herbert B. ; Casimiro, Mathew C. ; Wang, Chenguang ; Pestell, Richard G. ; Grieshaber, Philip ; Caro, Jaime ; Sotgia, Federica ; Lisanti, Michael P. / HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells : Autophagy drives compartment-specific oncogenesis. In: Cell Cycle. 2010 ; Vol. 9, No. 17. pp. 3534-3551.
@article{da807f25f851436fa9f37aadda1151e4,
title = "HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: Autophagy drives compartment-specific oncogenesis",
abstract = "Our recent studies have mechanistically implicated a loss of stromal Cav-1 expression and HIF1-alpha-activation in driving the cancer-associated fibroblast phenotype, through the paracrine production of nutrients via autophagy and aerobic glycolysis. However, it remains unknown if HIF1a-activation is sufficient to confer the cancer-associated fibroblast phenotype. To test this hypothesis directly, we stably-expressed activated HIF1a in fibroblasts and then examined their ability to promote tumor growth using a xenograft model employing human breast cancer cells (MDA-MB-231). Fibroblasts harboring activated HIF1a showed a dramatic reduction in Cav-1 levels and a shift towards aerobic glycolysis, as evidenced by a loss of mitochondrial activity, and an increase in lactate production. Activated HIF1a also induced BNIP3 and BNIP3L expression, markers for the autophagic destruction of mitochondria. Most importantly, fibroblasts expressing activated HIF1a increased tumor mass by ∼2-fold and tumor volume by ∼3-fold, without a significant increase in tumor angiogenesis. In this context, HIF1a also induced an increase in the lymph node metastasis of cancer cells. Similar results were obtained by driving NFκB activation in fibroblasts, another inducer of autophagy. Thus, activated HIF1a is sufficient to functionally confer the cancer-associated fibroblast phenotype. It is also known that HIF1a expression is required for the induction of autophagy in cancer cells. As such, we next directly expressed activated HIF1a in MDA-MB-231 cells and assessed its effect on tumor growth via xenograft analysis. Surprisingly, activated HIF1a in cancer cells dramatically suppressed tumor growth, resulting in a 2-fold reduction in tumor mass and a 3-fold reduction in tumor volume. We conclude that HIF1a activation in different cell types can either promote or repress tumorigenesis. Based on these studies, we suggest that autophagy in cancer-associated fibroblasts promotes tumor growth via the paracrine production of recycled nutrients, which can directly {"}feed{"} cancer cells. Conversely, autophagy in cancer cells represses tumor growth via their {"}self-digestion{"}. Thus, we should consider that the activities of various known oncogenes and tumor-suppressors may be compartment and cell-type specific, and are not necessarily an intrinsic property of the molecule itself. As such, other {"}classic{"} oncogenes and tumor suppressors will have to be re-evaluated to determine their compartment specific effects on tumor growth and metastasis. Lastly, our results provide direct experimental support for the recently proposed {"}Autophagic Tumor Stroma Model of Cancer{"}.",
keywords = "Autophagy, Cancer associated fibroblasts, Caveolin-1, Compartment-specific oncogenesis, HIF1A, Hypoxia, Mitophagy, NFκB, The Warburg effect, Tumor stroma",
author = "Barbara Chiavarina and Diana Whitaker-Menezes and Gemma Migneco and Martinez-Outschoorn, {Ubaldo E.} and Stephanos Pavlides and Anthony Howell and Tanowitz, {Herbert B.} and Casimiro, {Mathew C.} and Chenguang Wang and Pestell, {Richard G.} and Philip Grieshaber and Jaime Caro and Federica Sotgia and Lisanti, {Michael P.}",
year = "2010",
month = "9",
day = "1",
doi = "10.4161/cc.9.17.12908",
language = "English (US)",
volume = "9",
pages = "3534--3551",
journal = "Cell Cycle",
issn = "1538-4101",
publisher = "Landes Bioscience",
number = "17",

}

TY - JOUR

T1 - HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells

T2 - Autophagy drives compartment-specific oncogenesis

AU - Chiavarina, Barbara

AU - Whitaker-Menezes, Diana

AU - Migneco, Gemma

AU - Martinez-Outschoorn, Ubaldo E.

AU - Pavlides, Stephanos

AU - Howell, Anthony

AU - Tanowitz, Herbert B.

AU - Casimiro, Mathew C.

AU - Wang, Chenguang

AU - Pestell, Richard G.

AU - Grieshaber, Philip

AU - Caro, Jaime

AU - Sotgia, Federica

AU - Lisanti, Michael P.

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Our recent studies have mechanistically implicated a loss of stromal Cav-1 expression and HIF1-alpha-activation in driving the cancer-associated fibroblast phenotype, through the paracrine production of nutrients via autophagy and aerobic glycolysis. However, it remains unknown if HIF1a-activation is sufficient to confer the cancer-associated fibroblast phenotype. To test this hypothesis directly, we stably-expressed activated HIF1a in fibroblasts and then examined their ability to promote tumor growth using a xenograft model employing human breast cancer cells (MDA-MB-231). Fibroblasts harboring activated HIF1a showed a dramatic reduction in Cav-1 levels and a shift towards aerobic glycolysis, as evidenced by a loss of mitochondrial activity, and an increase in lactate production. Activated HIF1a also induced BNIP3 and BNIP3L expression, markers for the autophagic destruction of mitochondria. Most importantly, fibroblasts expressing activated HIF1a increased tumor mass by ∼2-fold and tumor volume by ∼3-fold, without a significant increase in tumor angiogenesis. In this context, HIF1a also induced an increase in the lymph node metastasis of cancer cells. Similar results were obtained by driving NFκB activation in fibroblasts, another inducer of autophagy. Thus, activated HIF1a is sufficient to functionally confer the cancer-associated fibroblast phenotype. It is also known that HIF1a expression is required for the induction of autophagy in cancer cells. As such, we next directly expressed activated HIF1a in MDA-MB-231 cells and assessed its effect on tumor growth via xenograft analysis. Surprisingly, activated HIF1a in cancer cells dramatically suppressed tumor growth, resulting in a 2-fold reduction in tumor mass and a 3-fold reduction in tumor volume. We conclude that HIF1a activation in different cell types can either promote or repress tumorigenesis. Based on these studies, we suggest that autophagy in cancer-associated fibroblasts promotes tumor growth via the paracrine production of recycled nutrients, which can directly "feed" cancer cells. Conversely, autophagy in cancer cells represses tumor growth via their "self-digestion". Thus, we should consider that the activities of various known oncogenes and tumor-suppressors may be compartment and cell-type specific, and are not necessarily an intrinsic property of the molecule itself. As such, other "classic" oncogenes and tumor suppressors will have to be re-evaluated to determine their compartment specific effects on tumor growth and metastasis. Lastly, our results provide direct experimental support for the recently proposed "Autophagic Tumor Stroma Model of Cancer".

AB - Our recent studies have mechanistically implicated a loss of stromal Cav-1 expression and HIF1-alpha-activation in driving the cancer-associated fibroblast phenotype, through the paracrine production of nutrients via autophagy and aerobic glycolysis. However, it remains unknown if HIF1a-activation is sufficient to confer the cancer-associated fibroblast phenotype. To test this hypothesis directly, we stably-expressed activated HIF1a in fibroblasts and then examined their ability to promote tumor growth using a xenograft model employing human breast cancer cells (MDA-MB-231). Fibroblasts harboring activated HIF1a showed a dramatic reduction in Cav-1 levels and a shift towards aerobic glycolysis, as evidenced by a loss of mitochondrial activity, and an increase in lactate production. Activated HIF1a also induced BNIP3 and BNIP3L expression, markers for the autophagic destruction of mitochondria. Most importantly, fibroblasts expressing activated HIF1a increased tumor mass by ∼2-fold and tumor volume by ∼3-fold, without a significant increase in tumor angiogenesis. In this context, HIF1a also induced an increase in the lymph node metastasis of cancer cells. Similar results were obtained by driving NFκB activation in fibroblasts, another inducer of autophagy. Thus, activated HIF1a is sufficient to functionally confer the cancer-associated fibroblast phenotype. It is also known that HIF1a expression is required for the induction of autophagy in cancer cells. As such, we next directly expressed activated HIF1a in MDA-MB-231 cells and assessed its effect on tumor growth via xenograft analysis. Surprisingly, activated HIF1a in cancer cells dramatically suppressed tumor growth, resulting in a 2-fold reduction in tumor mass and a 3-fold reduction in tumor volume. We conclude that HIF1a activation in different cell types can either promote or repress tumorigenesis. Based on these studies, we suggest that autophagy in cancer-associated fibroblasts promotes tumor growth via the paracrine production of recycled nutrients, which can directly "feed" cancer cells. Conversely, autophagy in cancer cells represses tumor growth via their "self-digestion". Thus, we should consider that the activities of various known oncogenes and tumor-suppressors may be compartment and cell-type specific, and are not necessarily an intrinsic property of the molecule itself. As such, other "classic" oncogenes and tumor suppressors will have to be re-evaluated to determine their compartment specific effects on tumor growth and metastasis. Lastly, our results provide direct experimental support for the recently proposed "Autophagic Tumor Stroma Model of Cancer".

KW - Autophagy

KW - Cancer associated fibroblasts

KW - Caveolin-1

KW - Compartment-specific oncogenesis

KW - HIF1A

KW - Hypoxia

KW - Mitophagy

KW - NFκB

KW - The Warburg effect

KW - Tumor stroma

UR - http://www.scopus.com/inward/record.url?scp=77956399348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956399348&partnerID=8YFLogxK

U2 - 10.4161/cc.9.17.12908

DO - 10.4161/cc.9.17.12908

M3 - Article

VL - 9

SP - 3534

EP - 3551

JO - Cell Cycle

JF - Cell Cycle

SN - 1538-4101

IS - 17

ER -